REG - Haleon PLC - Transactions in Own Shares

HALEONAnnouncement

Mon 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260608:nRSH2770Ha&default-theme=true

RNS Number : 2770H  Haleon PLC  08 June 2026

 

Haleon plc: Aggregated information - transactions in own shares

 

8 June 2026: Haleon plc (the "Company" or "Haleon") today announces the
purchase of 16,585,448 ordinary shares of £0.01 each in the Company (the
"Shares") for cancellation under its share buyback programme announced on 12
March 2026.

 

                                                    London Stock Exchange  CBOE (UK)/BXE  CBOE (UK)/CXE  Aquis
 Date of purchase:                                  1 June 2026
 Number of Shares purchased:                        3,673,823              2,784,141      884,017        438,324
 Highest price paid per Share (p):                  334.1000               333.9000       334.1000       333.6000
 Lowest price paid per Share (p):                   327.1000               326.9000       329.3000       330.5000
 Volume weighted average price paid per Share (p):  329.6854               329.5691       331.8523       332.1204
 Date of purchase:                                  2 June 2026
 Number of Shares purchased:                        3,592,476              1,992,902      893,149        445,097
 Highest price paid per Share (p):                  327.5000               327.1000       327.5000       326.6000
 Lowest price paid per Share (p):                   319.9000               319.9000       320.4000       321.2000
 Volume weighted average price paid per Share (p):  322.0103               321.7628       323.3163       323.6575
 Date of purchase:                                  3 June 2026
 Number of Shares purchased:                        1,750,781              45,821         48,613         35,602
 Highest price paid per Share (p):                  323.0000               323.0000       323.0000       323.0000
 Lowest price paid per Share (p):                   317.9000               319.2000       319.2000       319.2000
 Volume weighted average price paid per Share (p):  320.4053               320.8002       321.0249       320.8212
 Date of purchase:                                  4 June 2026
 Number of Shares purchased:                        113                    189            179            221
 Highest price paid per Share (p):                  324.0000               324.0000       324.0000       324.0000
 Lowest price paid per Share (p):                   324.0000               324.0000       324.0000       324.0000
 Volume weighted average price paid per Share (p):  324.0000               324.0000       324.0000       324.0000
 Date of purchase:                                  5 June 2026
 Number of Shares purchased:                        -                      -              -              -
 Highest price paid per Share (p):                  -                      -              -              -
 Lowest price paid per Share (p):                   -                      -              -              -
 Volume weighted average price paid per Share (p):  -                      -              -              -

 

Following the settlement of the above, the Company's registered share capital
is 8,842,752,346 ordinary shares of £0.01 each, of which 12,063,502 are
held as treasury shares. Therefore, the number of ordinary shares with voting
rights is 8,830,688,844 and this figure may be used by shareholders to
determine if they are required to notify their interest, or a change to their
interest, in Haleon under the FCA's Disclosure Guidance and Transparency
Rules.

 

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 as it
applies in the UK (the Market Abuse Regulation), a full breakdown of the
individual trades is available at the link below:

 

http://www.rns-pdf.londonstockexchange.com/rns/2770H_1-2026-6-5.pdf
(http://www.rns-pdf.londonstockexchange.com/rns/2770H_1-2026-6-5.pdf)

 

This announcement does not constitute, or form part of, an offer or any
solicitation of an offer for securities in any jurisdiction.

 

This announcement and individual trade breakdown will also be available on the
Company's website at: www.haleon.com/investors
(http://www.haleon.com/investors) .

 

 Enquiries

 Investors                                                                       Media

 Jo Russell                              +44 7787 392441                         Zoë Bird                             +44 7736 746167
 Rakesh Patel                            +44 7552 484646                         Victoria Durman                      +44 7894 505730
 Email: investor-relations@haleon.com (mailto:investor-relations@haleon.com)     Email: corporate.media@haleon.com (mailto:corporate.media@haleon.com)

 

About Haleon

Haleon (LSE/NYSE: HLN) is a consumer company that is solely focused on better
everyday health. Our people, our brands, our research, our investment and our
innovation are aimed at improving the everyday health of consumers. Our
product portfolio spans six major categories - Oral Health, Vitamins, Minerals
and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and
Therapeutic Skin Health and Other. Our superior brands - such as Advil,
Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and
Voltaren - are trusted by more than one billion consumers and are recommended
by health professionals around the world.

 

For more information, please visit www.haleon.com (http://www.haleon.com/)
.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  POSBLGDLRXGDGLU



            Copyright 2019 Regulatory News Service, all rights reserved